Flunarizine (HCl)

Flunarizine (HCl) is a sedating antihistamine and difluorinated derivative of cinnarizine. Flunarizine (HCl) is investigational calcium channel blocker. It has been reported in preliminary trials to effectively reduce the severity of the acute attack of migraine and prevent recurrences.

Brands
SIBELIUM POLYZINE FLUNZIC MIGRAM MIGRAM
Adult Dose
Dose: 5 mg
Single Dose: 5 (5)
Frequency: 12 hourly
Route: PO
Instructions:
Neonatal
Paedriatic
Characteristics
. It is of Synthetic origin and belongs to Piperazine. It belongs to Calcium L-channel antagonist pharmacological group on the basis of mechanism of action and also classified in Vasodilators pharmacological group.The Molecular Weight of Flunarizine (HCl) is 477.40. Its pKa is 7.7.
Contraindications
Flunarizine (HCl) is contraindicated in conditions like Depressive illness,Symptomatic parkinsonism,Hypersensitivity to the drug.
Effects
Flunarizine (HCl) produces potentially life-threatening effects which include Tremour, Rigidity, Orofacial dyskineria, Blady kinesia. which are responsible for the discontinuation of Flunarizine (HCl) therapy.The symptomatic adverse reactions produced by Flunarizine (HCl) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Drowsiness, Nausea, Diarrhea, Dry mouth, Asthenia, Heart burn, Dry mouth.
Indications
Flunarizine (HCl) is primarily indicated in conditions like Dizziness, Migraine prophylaxis, Tinnitus, Vertigo.
Interactions
No data regarding the interactions of Flunarizine (HCl) was found.
Interfrence
Risks
Drug should not be given to Pregnant Mothers.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Warnings
Patients should observed caution while driving or performing other tasks requiring alertness, because may cause drowsiness. Flunarizine should be used with caution in patients with liver impairment, dose should be reduced in patients with renal impairment. Avoid use in young children and use with caution in elderly patients.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.